GEMPLS: A New QSAR Method Combining Generic Evolutionary Method and Partial Least Squares

Yen-Chih Chen¹, Jinn-Moon Yang², Chi-Hung Tsai¹, and Cheng-Yan Kao¹

 ¹ Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan {r91051, d90008, cykao}@csie.ntu.edu.tw
 ² Department of Biological Science and Technology & Institute of Bioinformatics, National Chiao Tung University, Hsinchu, Taiwan moon@cc.nctu.edu.tw

Abstract. We have proposed a new method for quantitative structure-activity relationship (QSAR) analysis. This tool, termed GEMPLS, combines a genetic evolutionary method with partial least squares (PLS). We designed a new genetic operator and used Mahalanobis distance to improve predicted accuracy and speed up a solution for QSAR. The number of latent variables (lv) was encoded into the chromosome of GA, instead of scanning the best lv for PLS. We applied GEMPLS on a comparative binding energy (COMBINE) analysis system of 48 inhibitors of the HIV-1 protease. Using GEMPLS, the cross-validated correlation coefficient (q^2) is 0.9053 and external *SDEP* (*SDEP*_{ex}) is 0.61. The results indicate that GEMPLS is very comparative to GAPLS and GEMPLS is faster than GAPLS for this data set. GEMPLS yielded the QSAR models, in which selected residues are consistent with some experimental evidences.

1 Introduction

QSAR techniques are commonly regarded as a key role to computational molecular design. The major goal of QSAR is to formulate mathematical relationships between physicochemical properties of compounds and their experimentally determined *in vitro* biological activities. Thus the derived QSAR model can be subsequently used to predict the biological activities of new derivatives. A good QSAR model both enhances our understanding of the specifics of drug action and provides a theoretical foundation for lead optimization¹.

Many QSAR methodologies have been studied, such as comparative molecular field analysis (CoMFA)², the partial least square (PLS)³, comparative molecular binding energy analysis (COMBINE)^{4,5}. Among those methodologies, the PLS analysis is able to deal with strongly collinear input data and make no restriction on the number of variables used. Unfortunately, the predictive performance of PLS model drops and the PLS model becomes complicated when the number of features increases. Several feature selection methods for PLS have been proposed, in which genetic algorithm (GA) combined with PLS approach (GAPLS) has demonstrated the improvement on the prediction and interpretation of model⁶. The essence of GA is to

[©] Springer-Verlag Berlin Heidelberg 2005

mimics the metaphor of natural biological evolution. GA operates on a population of potential solutions applying the principle of survival of the fittest to produce successively better approximations to optimum solution. Hasegawa *et al.*⁷ examined a set of 48 human immunodeficiency virus type I (HIV-1) protease inhibitors by applying GAPLS to the variables derived from COMBINE. Several improved GAPLS models with significantly better predictability than the original study were formulated ^{5.7,8}.

However, the accuracy of GAPLS was still blemished by many features especially deriving from CoMFA or COMBINE. The numerous noise features, which GAPLS did not eliminated completely, were interfered with the significant features strongly correlating with biological activity. Besides, with regard to each possibly select feature set GAPLS needed to spend additional time to decide the optimum number of latent variables (*lv*) through PLS.

Here, we have developed an efficient method for evolving QSAR models by introducing a number of successive refinements which can be summarized as follows: 1) An extra bit lv, representing the number of latent variables, was appended to the chromosome of GA and expected to efficiently solve the problem of the optimum number of latent variables though evolutionary process; 2) Mahalanobis distance was adopted to select significant features from numerous features from COMBINE; 3) A new genetic operator, called biased mutation, was designed to lead the evolution of GA toward significant feature set and to reduce the interference of noise features. In this paper, we proposed a new QSAR method by integrating a generic evolutionary method, modified and enhanced from our previous works 9,10 and above issues, and PLS (GEMPLS). GEMPLS is general able to evolve the relationship between biological activities and compound features generated by other methods, such as CoMFA and COMBINE. Here we applied GEMPLS to evolve the QSAR models according to the interaction energy features generated by the COMBINE method on 48 HIV-1 protease inhibitors. Experiments show that GEMPLS is able to improve the predictability and efficiency, at the same time, the selected residues in the yielded QSAR model are consistent with some experimental evidences.

2 Material and Methods

Fig. 1 shows the main steps of applying GEMPLS in the COMBINE analysis: 1) prepare the inhibitor set and model protein-inhibitor complexes; 2) refine proteininhibitor complexes and calculate features (i.e., energy interactions); 3) select important features by Mahalanobis distance; 4) select features and evolve QSAR models. Each step is described in the following subsections.

2.1 COMBINE: Feature Extraction

The COMBINE analysis is the use of structural information about ligand-receptor complexes ^{4,5}. When the three-dimensional structure of macromolecule is available, ligand-receptor interaction energies could be calculated as features, which are subjected to statistical analysis in COMBINE. A subset of these features will be account

for the ligand affinity. The critical interaction patterns between ligands and the receptor could be identified and be used to derive the correlation of binding affinities.




Fig. 1. The framework and steps of GEMPLS applied in the COMBINE analysis

2.1.1 Prepare Data Sets and Model Protein-Inhibitor Complexes

Here, we have chosen 48 inhibitors of human immunodeficiency virus type I (HIV-1) protease studied in previous works ^{5,7,8}. The chemical structures of HIV-1 protease inhibitors and the 48 complexes were modeled on the crystallographic structure of the complex of HIV-1 protease with L-689,502 solved at 2.25A resolution ¹¹ using the interactive graphics program Insight II. All crystallographic waters were removed with the exception, which is involved in hydrogen bonding with the NH's of the flap residues IleA50 and IleB50 and the oxygen of the inhibitors ¹². All inhibitors were built using L-689, 502 as a template except for the more differential inhibitors 39-45, which employed the inhibitor saquinavir from the HIV-1 protease complex (protein data bank is 1c6z) as a template.

2.1.2 Refine Protein-Inhibitor Complexes and Calculate Features (Interactions)

Each complex model was performed a mild and progressive refinement. The flexibility of each inhibitor was manually explored as necessary to obtain a satisfactory conformation in the enzyme active site, which also corresponded to a low energy conformer. The docked conformation of an inhibitor was energy minimized in the three stages using the consistent valence force field, CVFF¹³. In the first stage, the hydrogen atoms of each complex were allowed reorient. Then the geometry of the inhibitor was optimized while the atoms of both the protein and the water were held fixed. Finally, the whole complex was energy minimized but the protein atoms were restrained to their crystallographic positions. Atom-centered charges for all the inhibitors were derived by fitting the molecular electrostatic potential calculated with the AM1 Hamiltonian¹⁴ to a monopole-monopole expression¹⁵.

The calculated ligand-receptor interaction energies in the refined complexes were partitioned on a per residue basis. Since HIV-1 protease has two protein subunits (subunit A and subunit B) of 99 amino acids, and two energy contributions (van der Waals and electrostatic) are considered for each residue. There are 396 features were yielded to characterize each protein-inhibitor complex. A data matrix was built with 396 columns representing each of the interaction energy features and with 48 rows representing each inhibitor in the data set.

2.2 GEMPLS: QSAR Model Evolution

PLS has played a critical role in the derivation of QSAR in CoMFA or COMBINE studies. Recently, more and more people recognize the benefits of feature selection before PLS regression. GAPLS has been shown as a practical solution. But when the number of features becomes large, GAPLS still has difficulty in driving out noises. And scanning for best lv is too inefficient and time consuming. Here, we introduce a number of successive enhancements, which are described in the following paragraphs, to construct our model GEMPLS to overcome the drawbacks of GAPLS.

The general idea of PLS is to try to extract these latent variables, accounting for as much of the manifest feature variation as possible while modeling the inhibitory activities well. To decide both the optimum number of latent variables and prediction error of a QSAR model, we defined the weighted standard deviation error of the predictions (WSDEP) as the scoring function of our GEMPLS:

$$WSDEP = \sqrt{\frac{\sum (y_i - y_{pred,i})^2}{N - lv - 1}} \left(\frac{100}{95}\right)^{lv}, \qquad (1)$$

where y_i and $y_{pred,i}$ are the observed and predicted inhibitory activities belong to inhibitor *i*, *N* is the total number of samples, and *lv* is the number of latent variables in the current model. In order to improve on the efficiency, we append an extra bit *lv*, representing the number of latent variables, to the original chromosome and expect GEMPLS model to efficiently solve the problem of the optimum number of latent variables though evolutionary process.

2.2.1 Select Features by Mahalanobis Distance

Mahalanobis distance is able be used to measure the deviation of a sample from the mean of the distribution in multivariable calculus. Therefore, the Mahalanobis distance is adopted to identify significant features from all of those.

$$M^{2} = (v - \mu)' \Sigma^{-1} (v - \mu) .$$
⁽²⁾

M is the Mahalanobis distance from the feature vector *v* (column vector of data matrix here) to the mean vector μ , where Σ is the covariance matrix of the features.

2.2.2 Feature Selections and QSAR Models Evolution

The inhibitory activity usually correlates with few important interaction energy features, that is, most of interaction energy features are meaningless or not apparently distinct from each other. GEM was applied to find out the significant interaction energy features and PLS was used to build the QSAR models based on these selected features. *WSDEP* was used as the objective function to provide a measure of how the internal predictability with respect to the selected features. The fittest individual will have the lowest *WSDEP*.

GEM, modified and enhanced from our previous works ^{9,10}, consists of five steps briefly described in the following:

(1) **Initiation and evaluation of the initial population** $(G_{t=0})$. Each chromosome is composed by an array of feature set and an lv value. For example, a chromosome has n+3 bits if the number of candidate feature is n and three bits for lv value. The initial population $(G_{t=1})$ of population size (N_p) is created by setting feature bits (0 denote the absence of corresponding feature, and 1 denote its presence) and an lv value (denote the number of latent variables and range in [1~5]) of each chromosome to random values and one, respectively. Then PLS is used to build a quasi-QSAR model, and evaluated by the scoring function (*WSDEP*), for each chromosome.

(2) Selection of the reproductive population. The chromosomes of reproductive population (P_sG_t) are selected from the population (G_t) with a fixed proportion (P_s) according to the stochastic universal sampling ¹⁶.

(3) Crossover and mutate the reproductive population (P_sG_t) . The offspring population (G_{off}) is generated by uniform crossover with a probability (crossover rate: P_c) and mutation operators, including uniform and biased mutation operators, with a probability (mutation rate: P_m).

(4) Evaluation of the offspring population (G_{off}) . PLS is then used to build a quasi-QSAR model, evaluated by *WSDEP*, for each chromosome in the offspring population.

(5) **Reinsertion of the child population.** To form the population of the next generation (G_{next}), the chromosomes of the current population (G_t) with lower objectives in the preceding (1- P_s) proportion are protected to the next generation, while the others are replaced with better ones from the offspring population (G_{off}). Let t = t+1 and $G_t = G_{next}$.

(6) The cycle of above four steps (from step 2 to 5) is repeated until the number of generation reaches to the maximum number of generations (N_{max}). The values of empirical parameters are defined as follows: $N_p = 100$, $N_{max} = 200$, $P_s = 0.9$, $P_c = 0.6$, and $P_m = 0.05$.

Biased Mutation. The uniform mutation may incur a risk of local convergence and slow evolution because plenty of features will raise the combinatorial complexity of feature space. To reduce the phenomena, the uniform mutation was cooperated with

biased mutation to lead the evolution of GA toward significant feature set and to reduce the interference of noise features.

$$F(x_i) = MIN + (MAX - MIN) \times \left(\frac{N_f - x_i}{N_f - 1}\right),$$
(3)

where $F(x_i)$ is the probability of selection of feature *i*; x_i is the rank of feature *i* in the descending order of Mahalanobis distance of all features, *MIN* and *MAX* are the lower and upper bounds, respectively, of probability of biased mutation; N_f is the number of significant features. The value of $F(x_i)$ is derived from x_i only when x_i is ahead of N_f , otherwise $F(x_i)$ is set to *MIN*. The meaning of $F(x_i)$ is that the more significant feature, the more higher probability of selection. In this study, *MAX*=0.8, *MIN*=0.2 and N_f =39.

2.3 Performance Evaluation

The predictability of QSAR model was assessed by the conventional correlation coefficient (r^2) , the cross-validated correlation coefficient (q^2) , the cross-validated *SDEP* $(SDEP_{ex})$, and external *SDEP* $(SDEP_{ex})$:

$$q^{2} = 1 - \frac{\sum (y_{i} - y_{pred,i})^{2}}{\sum (y_{i} - \overline{y})^{2}}, \qquad (4)$$

$$SDEP = \sqrt{\frac{\sum \left(y_i - y_{pred,i}\right)^2}{N}} , \qquad (5)$$

where y_i and $y_{pred,i}$ are the observed and predicted activity of inhibitor *i*, $y_{pred,i}$, respectively, \overline{y} is the average activity value of the inhibitor set, and *N* is the total number of inhibitors. The model with more remarkable predictability can provide the higher correlation coefficient (r^2 , q^2) and the lower *SDEP* between the observed and predicted inhibitory activities.

3 Results and Discussion

To evaluate the performance of PLS, GAPLS, and GEMPLS, 48 compounds shown in Table A (see appendix) were randomly divided into 6 subsets, and a six-fold cross validation was performed. For each round, one subset (8 compounds) was used as evaluation set, and other subsets (40 compounds) were used to train a QSAR model by Leave-One-Out method to optimize *WSDEP*. Table 1 shows the results, which were the average values of the six-fold cross validation. Five filter conditions (M>0, M>1, M>5, M>10, and M>15) of Mahalanobis distance of features were used to prescreen candidate features before GA feature selection steps. That is, there were five kinds of data matrices (48-by-396 (M>0), 48-by-188 (M>1), 48-by-85 (M>5), 48-by-59 (M>10), and 48-by-39 (M>15)) to be examined on those QSAR models according to these five conditions.

Table 1 shows the execution times, the numbers of selected features, and the values of lv of PLS, GAPLS and GEMPLS with five different Mahalanobis distance criteria. Several widely used performance measures, correlation coefficient (r^2) , cross-validated correlation coefficient (q^2) , cross-validated SDEP ($SDEP_{cv}$), external correlation coefficient (r^2_{ex}) , and external SDEP ($SDEP_{ex}$), were also summarized in Table 1. With the increasing of the degree of filter criteria, the better results were obtained for GEMPLS when the Mahalanobis distance threshold is less than 10. The highest $SDEP_{ex}$ (0.6080) was obtained by GEMPLS with Mahalanobis distance threshold 10. These results reveal that the usage of Mahalanobis distance could successfully discriminate significant features and reduce the ill effect of numerous features generated by the COMBINE method. But when the Mahalanobis distance threshold get higher, the performance degraded due to some important features were filtered out. The adjustment of proper amount of significant features would further improve the predictability and interpretation of QSAR models.

Table 1. The average predictive accuracies of PLS as well as GAPLS and GEMPLS with five different Mahalanobis distances for the HIV-1 protease by six-fold cross validation

Model ^a	Time(s) ^b	M-Features ^c	Features ^d	lv	r^2	q^2	SDEP _{cv}	r_{ex}^2	SDEP _{ex}
PLS	0.047	396	396	3	0.9177	0.8576	0.6031	0.7433	0.7454
GAPLS	11233.5	396	117.8	1	0.9107	0.9045	0.4718	0.6958	0.6582
GEMPLS-M0	1471.1	396	98.8	1	0.9091	0.9029	0.4754	0.7944	0.6464
GEMPLS-M1	766.7	188	42.3	1	0.9101	0.9040	0.4722	0.8030	0.6231
GEMPLS-M5	649.1	85	21.5	1	0.9110	0.9053	0.4691	0.8107	0.6115
GEMPLS-M10	485.3	59	19	1	0.9109	0.9046	0.4708	0.8126	0.6080
GEMPLS-M15	427.7	39	16.7	1	0.9084	0.9027	0.4757	0.7994	0.6284

^a GEMPLS-M0, M1, M5, M10, M15 mean that GEMPLS analysis performed with feature sets filtered by different Mahalanobis distance thresholds (i.e., 0, 1, 5, 10, and 15).

^b The executing time is measured on a single-processor of 1.4GHz/PentiumIV PC in seconds.

^c The number of candidate features is selected by the Mahalanobis distance.

^d The number of selected features is finally selected by GEMPLS and Mahalanobis distance.

The COMBINE method essentially generates numerous interaction energy features and the usage of Mahalanobis distance is able to reduce the number of these features. One of the evolutionary forces of GEMPLS is come from Mahalanobis distance between a wide distribution of features. At the same time, GEMPLS could decide the optimum number of latent variables for each chromosome though evolutionary process since the *lv* bit was encoded in the chromosome. Table 1 shows that GEMPLS is much faster than GAPLS and slightly better than GAPLS on this data set. Both GEMPLS and GAPLS outperform PLS. Figure 2 shows a typical QSAR model yielded by GEMPLS. This model reveals some experimental evidences. Figure 2(b) shows the features selected by GEMPLS and Figure 2(a) indicates the pseudo coefficients of the QSAR model evolved by PLS according to these selected features. This evolved QSAR model reflects some important residues of HIV-1 protease shown in Figure 2(c). Residues Asp25, Thr26, and Gly27 are highly conserved catalytic triad and Asp25 is essential to both catalytically and structurally. Residues Ala28 and Asp30 located at subsite S2. The mobile flap, residues 46-54, contains three characteristic regions: side chains that extend outward (Met46, Phe53), hydrophobic chains extending inward (Ile47, Ile54), and a glycine rich region. Residues Pro81, Val82, and Ile84 form the binding pocket. Residues Arg8 and Asp29 at the subsite S3, potentially bind polar residues. These results show that our QSAR model is able to yield many biological meanings.




Fig. 2. GEMPLS evolves a typical QSAR model of the HIV-1 protease. a) The pseudo coefficients of QSAR model, b) features selected by GEMPLS, and c) the important residues of the QSAR model are consistent with some experimental evidences

4 Conclusions

In summary, we have developed an evolutionary method with a novel scoring function for evolving QSAR models. By integrating a number of genetic operators, each having a unique search mechanism, GEMPLS blends the local and global searches so that they work cooperatively. Our scoring function is indeed able to enhance the prediction accuracy. GEMPLS not only increases the predictability and interpretation of a QSAR model, but also improves the performance and efficiency for feature selection. Our results demonstrate the applicability and adaptability of GEMPLS for QSAR models.

References

- Kubinyi, H. QSAR and 3-D QSAR in drug design. 2. Applications and problems. *Drug Discovery Today* 1997, 2, 538-546.
- (2) Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. *Journal of the American Chemical Society* 1988, *110*, 5959-5967.
- (3) Wold, S.; Johansson, E.; Cocchi, M. PLS Partial least-squares projections to latent structures. In H.Kubinyi Ed., 3D QSAR in Drug Design; Theory, Methods and Applications. ESCOM Science Publishers, Leiden Holland 1993.
- (4) Ortiz, A. R.; Pisabarro, M. T.; Gago, F.; Wade, R. C. Prediction of drug binding affinities by comparative binding energy analysis. *Journal of Medicinal Chemistry* 1995, *38*, 2681-2691.
- (5) Perez, C.; Pastor, M.; Ortiz, A. R.; Gago, F. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. *Journal of Medicinal Chemistry* **1998**, *41*, 836-852.
- (6) Wanchana, S.; Yamashita, F.; Hashida, M. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithmcombined partial least squares method. *Pharmaceutical Research* 2003, 20, 1401-1408.
- (7) Hasegawa, K.; Kimura, T.; Funatsu, K. GA Strategy for Variable Selection in QSAR Studies: Enhancement of Comparative Molecular Binding Energy Analysis by GA-Based PLS Method. *Quantitative Structure-Activity Relationships* **1999**, *18*, 262-272.
- (8) Holloway, B. A prior prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. *Journal of Medicinal Chemistry* 1995, 38, 305-317.
- (9) Yang, J.-M.; Chen, C.-C. GEMDOCK: a generic evolutionary method for molecular docking. *Proteins: Structure, Function, and Bioinformatics* **2004**, *55*, 288-304.
- (10) Yang, J. M.; Kao, C. Y. An evolutionary algorithm for the synthesis of multilayer coatings at oblique light incidence. *IEEE/OSA Journal of Lightwave Technology* 2001, 19, 559-570.
- (11) Thompson, W. J.; Fitzgerald, P. M.; Holloway, M. K.; Emini, E. A.; Darke, P. L. et al. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. *Journal of Medicinal Chemistry* 1992, 35, 1685-1701.
- (12) Wang, Y. X.; Freedberg, D. I.; Yamazaki, T.; Wingfield, P. T.; Stahl, S. J. et al. Solution NMR Evidence That the HIV-1 Protease Catalytic Aspartyl Groups Have Different Ionization States in the Complex Formed with the Asymmetric Drug KNI-272. *Biochemistry* 1996, *35*, 9945-9950.
- (13) Lifson, S.; Hagler, A. T.; Dauber, P. Consistent Force Field Studies of Intermolecular Forces in Hydrogen Bonded Crystals I: Carboxylic Acids, Amides, and the C=O...H Hydrogen Bonds. *Journal of the American Chemical Society* **1979**, *101*, 5111-5120.
- (14) Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. *Journal of the American Chemical Society* **1985**, *107*, 3902-3909.

- (15) Besler, B. H.; Merz, K. M.; Kollman, P. A. Atomic Charges Derived from Semiempirical Methods. *Journal of Computational Chemistry* **1990**, *11*, 431-439.
- (16) Baker, J. E. Reducing Bias and Inefficiency in the Selection Algorithm. *The Second International Conference on Genetic Algorithms and their Application* **1987**, 14-21.

Appendix:

Table A. HIV-1 protease inhibitors used in training set (1-32) and test set (33-48), and their corresponding observed inhibitory activities (pIC_{50})

No.	Chemical Structure	pIC ₅₀	No.	Chemical Structure	pIC ₅₀	No.	Chemical Structure	pIC ₅₀
1	$A_{o}f_{b}^{H} \overset{O}{\longrightarrow} f_{b}^{H} \overset{O}{\to} f_{h}^{H} \overset{O}} \overset{O}{\to} f_{h}^{\mathsf$	9.6	2	$A_{o}f_{b}^{f} \overset{o}{\longrightarrow} f_{b}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}}{\longrightarrow} f_{o}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}}{\longrightarrow} f_{o}^{h} \overset{o}}{\longrightarrow} f_{o}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}}{\longrightarrow} f_{o}^{h} \overset{o}{\longrightarrow} f_{o}^{h} \overset{o}{\to} \overset{o}{\to} f_{o}^{h} \overset{o}{\to} f_{o}^{h} \overset{o}{\to} \overset{o}{\to} f_{o}^{h} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}{\to} \overset{o}{\to} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}{\to} \overset{o} \overset{o}{\to} \overset{o}} \overset{o}} \overset{o}{\to} \overset{o}} \overset{o}} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}} \overset{o}{\to} \overset{o}} \overset{o}} \overset{o}{\to} \overset{o} \overset{o}} \overset{o} \overset{o}} $	8.11	3	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	9.72
4	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	9.59	5	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	9.64	6	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	9.22
7	$ = \sum_{p_{\rm ph}} \sum_{i=1}^{q_{\rm ph}} \sum_{i=1}^{q_{\rm ch}} \sum_{i=1}^{q_{\rm $	9.54	8	$ = \sum_{p_{\rm ph}} \sum_{i=1}^{Q_{\rm H}} \sum_{i=1}^{i_{\rm AH}} \sum_{j=1}^{i_{\rm A$	9.51	9	$ = \sum_{p_{\rm ph}} \sum_{i=1}^{q_{\rm $	9.57
10		5.53	11	$ = \sum_{p_{\rm ph}} \sum_{i=1}^{q_{\rm $	9.8	12		7.56
13	$ = \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum$	9.14	14	$ = \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum$	8.27	15	$ = \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum$	9.28
16	$ = \sum_{p_{\rm ph}} \sum_{i=1}^{q_{\rm H}} \sum_{j=1}^{s_{\rm Ph}} \sum_{i=1}^{q_{\rm H}} \sum_{j=1}^{s_{\rm Ph}} \sum_{j=1}^{q_{\rm H}} \sum_{j=1}^{s_{\rm Ph}} \sum_{j=1}^{s_{\rm Ph}$	9.6	17	$A_{b}^{o}f_{b}^{H} \overset{o}{\overset{o}}f_{b}^{d} \overset{o}{\overset{d}}f_{b}^{d} \overset{o}{\overset{d}}f_{b}^{d} \overset{o}{\overset{d}}f_{b}^{d}$	9.77	18	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} $	6.94
19	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} $	8.02	20		7.47	21	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} $	6.16
22		6.79	23	$ \qquad \qquad$	7.18	24		6.67
25	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array} \\ \end{array} \\ \end{array} \\ \end{array}$	6.91	26		9.16	27		9.75
28	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	7.39	29		6.89	30		6.84
31	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	10	32	H J PH CH	7.41	33		6.23
34		9.16	35	$\operatorname{Act}_{P_{H}}^{H} \xrightarrow{O}_{H}^{H} \xrightarrow{O}_{H}^{H} \xrightarrow{O}_{H}^{H}$	6.25	36	$\begin{array}{c} \sim \\ \qquad \qquad$	8.89
37	$\sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{i$	10.22	38	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \\ \end{array} $	5.9	39	$\bigcap_{i=1}^{NH_2} \bigcap_{i=1}^{NH_2} \bigcap_{i=1}^{QH} \bigcap_{i=1}^{H_0} \bigcap_{i=1}^{QH} \bigcap_{i=1}^{H_0} $	9.64

No.	Chemical Structure	pIC ₅₀	No.	Chemical Structure	pIC ₅₀	No.	Chemical Structure	pIC ₅₀
40		8.27	41		10.27	42		7.28
43		5.17	44		5.52	45		8.12
46	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	6.64	47	$A_{o}f_{h}^{o}f_{h}^{o}f_{h}^{o}f_{h}^{o}h}f_{o}h^{h$	5.33	48	$Aut_{H} Aut_{H} $	5.86